Related Experiment Videos
Intraperitoneal chemotherapy for malignant peritoneal mesothelioma
L T Vlasveld1, M P Gallee, S Rodenhuis
1Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1991
Summary
Intraperitoneal chemotherapy shows promise for malignant peritoneal mesothelioma. Cisplatin-based regimens offer potential for complete remission, suggesting it as a leading treatment option.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Malignant peritoneal mesothelioma is a rare and aggressive cancer.
- Treatment options for this condition are limited.
Observation:
- Four patients with malignant peritoneal mesothelioma received intraperitoneal chemotherapy.
- One patient achieved a complete remission lasting over 36 months.
- Another patient experienced a partial remission for 10 months.
Findings:
- Literature review of 70 patients indicates a 58% response rate with intraperitoneal chemotherapy.
- Complete remissions were observed in 24% of patients in the reviewed literature.
- Cisplatin-based intraperitoneal chemotherapy demonstrated efficacy in the studied patients.
Implications:
- Intraperitoneal chemotherapy, particularly cisplatin-based, appears to be a viable treatment for malignant peritoneal mesothelioma.
- Further research is warranted to confirm efficacy due to patient group heterogeneity.
- This approach may offer significant remission durations for selected patients.